Abaloparatide
Also known as: Tymlos, BA058
Abaloparatide is a synthetic parathyroid hormone-related protein (PTHrP) analog that selectively activates the PTH1 receptor to stimulate bone formation. This peptide increases bone mineral density and reduces fracture risk by promoting osteoblast activity while minimally affecting bone resorption.
Abaloparatide is a 3961.6 Da research peptide. Abaloparatide is a synthetic parathyroid hormone-related protein (PTHrP) analog that selectively activates the PTH1 receptor to stimulate bone formation. This peptide increases bone mineral density and reduces fracture risk by promoting osteoblast activity while minimally affecting bone resorption.
Also called: Tymlos, BA058
3961.6
Molecular Weight
Daltons
4
Strong Evidence
benefits
4
Studies Cited
peer-reviewed
40-80
Typical Dose
mcg
Overview
Abaloparatide represents a targeted approach to treating bone disorders through selective PTH1 receptor activation. Unlike full PTH agonists, this synthetic analog preferentially binds to the RG conformation of the PTH1 receptor, which favors the Gs signaling pathway over Gq/11 pathways. This selectivity translates to enhanced bone formation with reduced hypercalcemic effects. The peptide stimulates osteoblast proliferation and differentiation through cyclic adenosine monophosphate (cAMP) signaling, leading to increased collagen synthesis and mineralization. Research demonstrates that abaloparatide promotes cortical and trabecular bone formation while having minimal impact on bone resorption markers. The peptide's unique binding profile results in transient receptor activation, which appears optimal for anabolic bone effects. Studies indicate that abaloparatide treatment leads to significant improvements in bone microarchitecture, including increased trabecular thickness, connectivity, and cortical porosity reduction. The compound shows particular promise in postmenopausal osteoporosis research and conditions requiring rapid bone formation.
Key Takeaways: Abaloparatide
- Strongest evidence supports Abaloparatide for increased bone mineral density and reduced fracture risk
- Research doses typically range from 40 to 80 mcg via subcutaneous
- 4 benefits with strong evidence, 3 moderate, 0 preliminary
- Half-life: 1.7 hours (subcutaneous)
- 4 cited research studies in this guide
Mechanism of Action
Abaloparatide selectively activates the PTH1 receptor by preferentially binding to the RG conformation, which couples primarily to Gs proteins rather than Gq/11 pathways. This selective activation increases intracellular cAMP levels in osteoblasts and osteocytes, leading to enhanced bone formation through increased osteoblast number, activity, and survival. The peptide stimulates the expression of bone formation markers including osteocalcin, procollagen type I N-propeptide (P1NP), and bone-specific alkaline phosphatase. Unlike continuous PTH exposure, the transient receptor activation pattern of abaloparatide favors anabolic over catabolic bone effects by minimizing osteoclast stimulation.
Research Benefits
Abaloparatide at a Glance
Abaloparatide selectively activates the PTH1 receptor by preferentially binding to the RG conformation, which couples primarily to Gs proteins rather than Gq/11 pathways.
Increased Bone Mineral Density
Strong EvidenceAbaloparatide significantly increases BMD at the lumbar spine, total hip, and femoral neck through enhanced osteoblast activity and bone formation rate, with studies showing 4-9% increases in spine BMD over 18 months.
Reduced Fracture Risk
Strong EvidenceResearch demonstrates 43% reduction in vertebral fractures and 84% reduction in major osteoporotic fractures compared to placebo, achieved through improved bone microarchitecture and cortical thickness.
Enhanced Trabecular Microarchitecture
Strong EvidenceThe peptide improves trabecular bone volume, thickness, and connectivity while reducing trabecular separation, leading to stronger bone structure and improved mechanical properties.
Rapid Bone Formation Response
Strong EvidenceBone formation markers including P1NP and osteocalcin increase within 1-3 months of treatment initiation, indicating rapid anabolic bone response and accelerated bone modeling.
Cortical Bone Strengthening
Moderate EvidenceAbaloparatide increases cortical thickness and reduces cortical porosity, particularly at weight-bearing sites, contributing to improved bone strength and fracture resistance.
Lower Hypercalcemia Risk
Moderate EvidenceCompared to full PTH agonists, abaloparatide demonstrates reduced incidence of hypercalcemia and hypercalciuria due to its selective receptor activation profile.
Improved Bone Quality Markers
Moderate EvidenceTreatment enhances bone quality parameters including mineral-to-matrix ratio and collagen cross-linking, contributing to improved bone mechanical properties beyond density changes.
Research Dosing Protocols
Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
| Research Protocol | Dose Range | Route |
|---|---|---|
| Osteoporosis research | 40–80 mcg | subcutaneous |
| Bone formation studies | 20–80 mcg | subcutaneous |
| Fracture prevention research | 80–80 mcg | subcutaneous |
Frequency
Once daily
Timing
Morning administration preferred
Cycle Length
18-24 months maximum
Research Notes
- 1Rotate injection sites to prevent lipodystrophy
- 2Allow refrigerated solution to reach room temperature before injection
- 3Maximum treatment duration should not exceed 2 years due to osteosarcoma concerns
- 4Baseline and periodic monitoring of serum calcium levels recommended
- 5Discontinue if persistent hypercalcemia develops
Reconstitution Guide
Standard Reconstitution
Vial Size
3 mg
Bacteriostatic Water
3 mL
Concentration
10 mcg
per 0.1 mL (10 units)
Step-by-Step Guide
Gather Materials
Abaloparatide vial, bacteriostatic water, alcohol swabs, insulin syringes.
Equilibrate Temperature
Remove the vial from storage and allow it to reach room temperature (5-10 minutes).
Sanitize
Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.
Draw Water
Draw 3 mL of bacteriostatic water into a syringe.
Add Water to Vial
Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.
Mix Gently
Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.
Store Properly
Refrigerate at 2-8°C (refrigerated). 30 days after first use.
Storage Temperature
2-8°C (refrigerated)
Shelf Life
30 days after first use
Important Notes
- •Pre-filled pen devices are typically used in research settings
- •Do not freeze or shake vigorously
- •Protect from light during storage
- •Single-use devices should be discarded after 30 days
- •Inspect for particulates or discoloration before use
Abaloparatide Dosing Calculator
Calculate daily intake, cycle totals, and vials needed with pre-filled protocols →
Abaloparatide Reconstitution Calculator
Calculate concentration, syringe units, and doses per vial with auto-filled values →
Safety & Side Effects
Reported Side Effects
- !Injection site reactions (redness, swelling, pain)
- !Nausea and vomiting
- !Dizziness and headache
- !Hypercalciuria (elevated urine calcium)
- !Mild hypercalcemia
- !Upper respiratory tract infections
- !Arthralgia and back pain
- !Fatigue and weakness
- !Constipation
- !Potential osteosarcoma risk (theoretical, based on animal studies)
Potential Interactions
- ⚡Thiazide diuretics may increase risk of hypercalcemia
- ⚡Calcium supplements may potentiate hypercalcemic effects
- ⚡Vitamin D analogs increase calcium absorption and hypercalcemia risk
- ⚡Bisphosphonates may antagonize anabolic bone effects
- ⚡Loop diuretics may increase calcium excretion and reduce efficacy
Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.
Research Studies
The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.
Abaloparatide for osteoporosis: a review of clinical efficacy and safety
Comprehensive review of abaloparatide clinical trials showing superior bone formation effects and lower hypercalcemia incidence compared to teriparatide.
Bone histomorphometry in transiliac bone biopsies from patients treated with abaloparatide
Histomorphometric analysis demonstrating increased bone formation rate, osteoblast surface, and improved trabecular architecture following abaloparatide treatment.
The anabolic effects of abaloparatide-SC are greater than teriparatide when assessed by histomorphometry
Direct comparison study showing abaloparatide produces greater increases in bone formation parameters and trabecular connectivity versus teriparatide.
Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits
Preclinical study demonstrating dose-dependent increases in BMD and bone mechanical strength in osteoporotic rabbit model.
Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.
Frequently Asked Questions
Abaloparatide shows greater selectivity for the PTH1 receptor RG conformation, resulting in more potent bone formation effects with lower risk of hypercalcemia compared to teriparatide. Clinical studies demonstrate superior BMD gains and fracture reduction with abaloparatide.
Research doses typically range from 20-80 mcg daily via subcutaneous injection, with 80 mcg being the most studied dose for osteoporosis research. Treatment duration should not exceed 24 months due to theoretical osteosarcoma concerns.
Bone formation markers like P1NP and osteocalcin typically increase within 1-3 months of starting abaloparatide treatment, with peak anabolic effects observed around 6-12 months of continuous therapy.
Animal studies showed increased osteosarcoma risk at high doses, leading to a black box warning. However, no cases have been reported in human clinical trials. The theoretical risk limits treatment duration to 2 years maximum.
The most frequent side effects include injection site reactions, nausea, dizziness, and mild hypercalcemia. Most adverse effects are mild to moderate and decrease over time with continued treatment.
Yes, baseline and periodic serum calcium monitoring is recommended due to the peptide's effects on calcium homeostasis. Discontinuation is advised if persistent hypercalcemia develops during treatment.
Pre-filled pens should be stored refrigerated at 2-8°C and protected from light. After first use, the device remains stable for 30 days when properly stored. Never freeze or shake the medication.
Concurrent use is not recommended as bisphosphonates may interfere with abaloparatide's anabolic bone effects. Sequential therapy (abaloparatide followed by antiresorptive therapy) is the preferred approach in research protocols.
Research & Educational Use Only
All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.